Monitoring and reversal of anticoagulation and antiplatelets

Interventional Cardiology Clinics

Volumn 2, Issue 4, 2013, Pages 643-663

  Yost, Gregory W ^a   Steinhubl, Steven R ^a  

^a GEISINGER MEDICAL CENTER   (United States)

Author keywords

Anticoagulation; Antiplatelets; Antithrombotics; Bleeding; Monitoring; PCI; Reversal

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ARGATROBAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CANGRELOR; CLOPIDOGREL; DESMOPRESSIN; ENOXAPARIN; EPTIFIBATIDE; FONDAPARINUX; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; PRASUGREL; PROTAMINE SULFATE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN INHIBITOR; TICAGRELOR; TICLOPIDINE; TIROFIBAN;

ACUTE CORONARY SYNDROME; ANTICOAGULATION; BLEEDING; CONTINUOUS INFUSION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG INDICATION; DRUG MONITORING; DRUG SAFETY; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INCIDENCE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; POINT OF CARE TESTING; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SINGLE DRUG DOSE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STABLE ANGINA PECTORIS; STENT THROMBOSIS; UNSTABLE ANGINA PECTORIS;

EID: 84884985386     PISSN: 22117458     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.iccl.2013.05.008     Document Type: Review

References (146)

1. Kolandaivelu K., Swaminathan R., Gibson W.J., et al. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings/clinical perspective. Circulation 2011, 123:1400-1409.
2. Van Belle E., Tio F.O., Couffinhal T., et al. Stent endothelialization. Circulation 1997, 95:438-448.
3. Xie Y., Takano M., Murakami D., et al. Comparison of neointimal coverage by optical coherence tomography of a sirolimus-eluting stent versus a bare-metal stent three months after implantation. Am J Cardiol 2008, 102:27-31.
4. Levine G.N., Bates E.R., Blankenship J.C., et al. ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011, 124:e574-e651.
5. Popma J.J., Weitz J., Bittl J.A., et al. Antithrombotic therapy in patients undergoing coronary angioplasty. Chest 1998, 114:728S-741S.
6. Gruntzig A. Transluminal dilatation of coronary-artery stenosis. Lancet 1978, 1:263.
7. Gruntzig A., Hirzel H., Goebel N., et al. Percutaneoustransluminal dilatation of chronic coronary stenoses. First experiences. Schweiz Med Wochenschr 1978, 108:1721-1723. [in German].
8. Fischman D.L., Leon M.B., Baim D.S., et al. Arandomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. NEngl J Med 1994, 331:496-501.
9. Serruys P.W., Jaegere P., Kiemeneij F., et al. Acomparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. NEngl J Med 1994, 331:489-495.
10. Harding S.A., Walters D.L., Palacios I.F., et al. Adjunctive pharmacotherapy for coronary stenting. Curr Opin Cardiol 2001, 16:293-299.
11. Hochholzer W., Wiviott S.D., Antman E.M., et al. Predictors of bleeding and time dependence of association of bleeding with mortality/clinical perspective. Circulation 2011, 123:2681-2689.
12. Rao S.V., Ohman E.M. Anticoagulant therapy for percutaneous coronary intervention. Circ Cardiovasc Interv 2010, 3:80-88.
13. O'Neill B.P., Shaw E.S., Cohen M.G. Anticoagulation in percutaneous coronary intervention. Intervent Cardiol 2010, 2:559-577.
14. Garg R., Uretsky B.F., Lev E.I. Anti-platelet and anti-thrombotic approaches in patients undergoing percutaneous coronary intervention. Catheter Cardiovasc Interv 2007, 70:388-406.
15. Hirsh J.A., Sonia S., Halperin J.L., et al. Guide to anticoagulant therapy: heparin: a statement for healthcare professionals from the American Heart Association. Circulation 2001, 103:2994-3018.
16. Cohen M., Adams P.C., Parry G., et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users: primary end points analysis from the ATACS Trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group. Circulation 1994, 89:81-88.
17. Oler A.W., Mary A., Oler J.G., et al. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: a meta-analysis. JAMA 1996, 276:811-815.
18. Neri Serneri G.G., Rovelli F., Gensini G.F., et al. Effectiveness of low-dose heparin in prevention of myocardial reinfarction. Lancet 1987, 1:937-942.
19. Li Y., Rha S.W., Chen K., et al. Low-molecular-weight heparin versus unfractionated heparin in acute ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with drug-eluting stents. Am Heart J 2010, 159:684-690.e1.
20. Montalescot G., Collet J.P., Lison L., et al. Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. JAm Coll Cardiol 2000, 36:110-114.
21. De Feyter P.J., Van Den Brand M., Laarman G.J., et al. Acute coronary artery occlusion during and after percutaneous transluminal coronary angioplasty: frequency, prediction, clinical course, management, and follow-up. Circulation 1991, 83:927-936.
22. Young E., Prins M., Levine M.N., et al. Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost 1992, 67:639-643.
23. Marciniak E. Factor-Xa inactivation by antithrombin. 3. Evidence for biological stabilization of factor Xa by factor V-phospholipid complex. Br J Haematol 1973, 24:391-400.
24. Hirsh J., Warkentin T.E., Raschke R., et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998, 114:489S-510S.
25. Xiao Z., Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 1998, 97:251-256.
26. D'Angelo A., Seveso M.P., D'Angelo S.V., et al. Effect of clot-detection methods and reagents on activated partial thromboplastin time (APTT). Implications in heparin monitoring by APTT. Am J Clin Pathol 1990, 94:297-306.
27. McGarry T.F., Gottlieb R.S., Morganroth J., et al. The relationship of anticoagulation level and complications after successful percutaneous transluminal coronary angioplasty. Am Heart J 1992, 123:1445-1451.
28. Ferguson J.J., Dougherty K.G., Gaos C.M., et al. Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty. JAm Coll Cardiol 1994, 23:1061-1065.
29. Narins C.R., Hillegass W.B., Nelson C.L., et al. Relation between activated clotting time during angioplasty and abrupt closure. Circulation 1996, 93:667-671.
30. Chew D.P., Bhatt D.L., Lincoff A.M., et al. Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. Circulation 2001, 103:961-966.
31. Brener S.J., Moliterno D.J., Lincoff A.M., et al. Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention. Circulation 2004, 110:994-998.
32. Montalescot G., Cohen M., Salette G., et al. Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial. Eur Heart J 2008, 29:462-471.
33. Doherty T.M., Shavelle R.M., French W.J. Reproducibility and variability of activated clotting time measurements in the cardiac catheterization laboratory. Catheter Cardiovasc Interv 2005, 65:330-337.
34. Levine G.N., Bates E.R., Blankenship J.C., et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. JAm Coll Cardiol 2011, 58:e44-e122.
35. Weitz J.I. Blood coagulation and anticoagulant, fibrinolytic, and antiplatelet drugs. Goodman & Gilman's the pharmacological basis of therapeutics 2011, McGraw-Hill, New York, Available at:, Accessed January 10, 2013. http://www.accessmedicine.com/content.aspx?aID%3D16668944, 12th edition. L.L. Brunton, B.A. Chabner, B.C. Knollmann (Eds.).
36. Wakefield T.W., Hantler C.B., Wrobleski S.K., et al. Effects of differing rates of protamine reversal of heparin anticoagulation. Surgery 1996, 119:123-128.
37. Garcia D.A., Baglin T.P., Weitz J.I., et al. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012, 141:e24S-e43S.
38. Harenberg J. Pharmacology of low molecular weight heparins. Semin Thromb Hemost 1990, 16:12-18.
39. Kadakia R.A., Baimeedi S.R., Ferguson J.J. Low-molecular-weight heparins in the cardiac catheterization laboratory. Tex Heart Inst J 2004, 31:72-83.
40. Kleinschmidt K., Charles R. Pharmacology of low molecular weight heparins. Emerg Med Clin North Am 2001, 19:1025-1049.
41. Antman E.M. The search for replacements for unfractionated heparin. Circulation 2001, 103:2310-2314.
42. Weitz J.I. Low-molecular-weight heparins. NEngl J Med 1997, 337:688-699.
43. Ferguson J.J., Antman E.M., Bates E.R., et al. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study. Am Heart J 2003, 146:628-634.
44. Gurfinkel E.P., Manos E.J., Mejaíl R.I., et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. JAm Coll Cardiol 1995, 26:313-318.
45. Klein W., Buchwald A., Hillis S.E., et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease: Fragmin in Unstable Coronary Artery Disease Study (FRIC). Circulation 1997, 96:61-68.
46. Cohen M., Demers C., Gurfinkel E.P., et al. Acomparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. NEngl J Med 1997, 337:447-452.
47. Antman E.M. The Thrombolysis in Myocardial Infarction B Trial Investigators. TIMI 11B. Enoxaparin versus unfractionated heparin for unstable angina or non-Q-wave myocardial infarction: a double-blind, placebo-controlled, parallel-group, multicenter trial. Rationale, study design, and methods. Am Heart J 1998, 135:S353-S360.
48. Antman E.M., Cohen M., Radley D., et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction: TIMI 11B-ESSENCE meta-analysis. Circulation 1999, 100:1602-1608.
49. SYNERGY Trial Investigators Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004, 292:45-54.
50. Drouet L., Bal Dit Sollier C., Martin J. Adding intravenous unfractionated heparin to standard enoxaparin causes excessive anticoagulation not detected by activated clotting time: results of the STACK-on to ENOXaparin (STACKENOX) study. Am Heart J 2009, 158:177-184.
51. Montalescot G., White H.D., Gallo R., et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. NEngl J Med 2006, 355:1006-1017.
52. Kereiakes D.J., Grines C., Fry E., et al. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. JInvasive Cardiol 2001, 13:272-278.
53. Bhatt D.L., Lee B.I., Casterella P.J., et al. Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the coronary revascularization using integrilin and single bolus enoxaparin study. JAm Coll Cardiol 2003, 41:20-25.
54. Dumaine R., Borentain M., Bertel O., et al. Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention: quantitative review of randomized trials. Arch Intern Med 2007, 167:2423-2430.
55. Gallo R., Steinhubl S.R., White H.D., for the STEEPLE Investigators, et al. Impact of anticoagulation regimens on sheath management and bleeding in patients undergoing elective percutaneous coronary intervention in the STEEPLE trial. Catheter Cardiovasc Interv 2009, 73:319-325.
56. Henry T.D., Satran D., Knox L.L., et al. Are activated clotting times helpful in the management of anticoagulation with subcutaneous low-molecular-weight heparin?. Am Heart J 2001, 142:590-593.
57. Linkins L., Julian J.A., Rischke J., et al. Invitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation. Thromb Res 2002, 107:241-244.
58. Abbate R., Gori A.M., Farsi A., et al. Monitoring of low-molecular-weight heparins in cardiovascular disease. Am J Cardiol 1998, 82:33L-36L.
59. Choussat R., Montalescot G., Collet J.P., et al. Aunique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention. JAm Coll Cardiol 2002, 40:1943-1950.
60. Collet J.P., Montalescot G., Lison L., et al. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation 2001, 103:658-663.
61. Montalescot G., Collet J.P., Tanguy M.L., et al. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation 2004, 110:392-398.
62. Martin J.L., Fry E.T., Sanderink G.C., et al. Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: the pharmacokinetics of enoxaparin in PCI (PEPCI) study. Catheter Cardiovasc Interv 2004, 61:163-170.
63. Rouby S.E., Cohen M., Gonzales A., et al. Point-of-care monitoring of enoxaparin in the presence of GpIIb/IIIa combined therapy during percutaneous coronary interventions. Point Care 2005, 4:30-35.
64. Moliterno D.J., Mukherjee D. Applications of monitoring platelet glycoprotein IIb/IIIa antagonism and low molecular weight heparins in cardiovascular medicine. Am Heart J 2000, 140:S136-S142.
65. Moliterno D.J., Hermiller J.B., Kereiakes D.J., et al. Anovel point-of-care enoxaparin monitor for use during percutaneous coronary intervention. Results of the Evaluating Enoxaparin Clotting Times (ELECT) Study. JAm Coll Cardiol 2003, 42:1132-1139.
66. Lim W., Dentali F., Eikelboom J.W., et al. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006, 144:673-684.
67. Popma J.J., Berger P., Ohman E.M., et al. Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004, 126:576S-599S.
68. Lindblad B., Borgstrom A., Wakefield T.W., et al. Protamine reversal of anticoagulation achieved with a low molecular weight heparin. The effects on eicosanoids, clotting and complement factors. Thromb Res 1987, 48:31-40.
69. Levi M., Eerenberg E., Kamphuisen P.W. Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. JThromb Haemost 2011, 9:1705-1712.
70. Vuillemenot A., Schiele F., Meneveau N., et al. Efficacy of a synthetic pentasaccharide, a pure factor Xa inhibitor, as an antithrombotic agent-a pilot study in the setting of coronary angioplasty. Thromb Haemost 1999, 81:214-220.
71. Coussement P.K., Bassand J.P., Convens C., et al. Asynthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study. Eur Heart J 2001, 22:1716-1724.
72. Simoons M.L., Bobbink I.W., Boland J., et al. Adose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study. JAm Coll Cardiol 2004, 43:2183-2190.
73. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators, Yusuf S., Mehta S.R., et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. NEngl J Med 2006, 354:1464-1476.
74. Mehta S.R., Steg P.G., Granger C.B., et al. Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial. Circulation 2005, 111:1390-1397.
75. Yusuf S., Mehta S.R., Chrolavicius S., et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 2006, 295:1519-1530.
76. Mehta S.R., Boden W.E., Eikelboom J.W., et al. Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials. Circulation 2008, 118:2038-2046.
77. Bijsterveld N.R., Moons A.H., Boekholdt S.M., et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 2002, 106:2550-2554.
78. Topol E.J., Bonan R., Jewitt D., et al. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation 1993, 87:1622-1629.
79. Bittl J.A., Strony J., Brinker J.A., et al. Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. NEngl J Med 1995, 333:764-769.
80. Bates S.M., Weitz J.I. The mechanism of action of thrombin inhibitors. JInvasive Cardiol 2000, 12:27F-32F.
81. Wong C., White H.D. Direct antithrombins: mechanisms, trials, and role in contemporary interventional medicine. Am J Cardiovasc Drugs 2007, 7:249-257.
82. Lewis B.E., Hursting M.J. Direct thrombin inhibition during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Expert Rev Cardiovasc Ther 2007, 5:57-68.
83. Lee C.J., Ansell J.E. Direct thrombin inhibitors. Br J Clin Pharmacol 2011, 72:581-592.
84. White H.D., Aylward P.E., Frey M.J., et al. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Circulation 1997, 96:2155-2161.
85. Kong D.F., Topol E.J., Bittl J.A., et al. Clinical outcomes of bivalirudin for ischemic heart disease. Circulation 1999, 100:2049-2053.
86. Bittl J.A., Chaitman B.R., Feit F., et al. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J 2001, 142:952-959.
87. Lincoff A., Michael Bittl J.A., Harrington R.A., et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 Randomized Trial. JAMA 2003, 289:853-863.
88. Kastrati A., Neumann F., Schulz S., et al. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. NEngl J Med 2011, 365:1980-1989.
89. Stone G.W., Witzenbichler B., Guagliumi G., et al. Bivalirudin during primary PCI in acute myocardial infarction. NEngl J Med 2008, 358:2218-2230.
90. Moen M.D., Keating G.M., Wellington K. Bivalirudin: a review of its use in patients undergoing percutaneous coronary intervention. Drugs 2005, 65:1869-1891.
91. Rossig L., Genth-Zotz S., Rau M., et al. Argatroban for elective percutaneous coronary intervention: the ARG-E04 multi-center study. Int J Cardiol 2011, 148:214-219.
92. Akimoto K., Klinkhardt U., Zeiher A., et al. Anticoagulation with argatroban for elective percutaneous coronary intervention: population pharmacokinetics and pharmacokinetic-pharmacodynamic relationship of coagulation parameters. JClin Pharmacol 2011, 51:805-818.
93. van Werkum J.W., Hackeng C.M., Smit J.J., et al. Monitoring antiplatelet therapy with point-of-care platelet function assays: a review of the evidence. Future Cardiol 2008, 4:33-55.
94. Steinhubl S.R., Berger P.B., Mann J.T., CREDO Investigators, Clopidogrel for the Reduction of Events During Observation, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002, 288:2411-2420.
95. Becker R., Meade T., Berger P., et al. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008, 133:776S-814S.
96. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324:71-86. Antithrombotic Trialists' Collaboration.
97. Reiter R.A., Jilma B. Platelets and new antiplatelet drugs. Therapy 2005, 2:465-502.
98. Holmes D.R., Kereiakes D.J., Kleiman N.S., et al. Combining antiplatelet and anticoagulant therapies. JAm Coll Cardiol 2009, 54:95-109.
99. Campbell C.L., Smyth S., Montalescot G., et al. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA 2007, 297:2018-2024.
100. Peters R.J., Mehta S.R., Fox K.A., et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003, 108:1682-1687.
101. Steinhubl S.R. Historical observations on the discovery of platelets, platelet function testing and the first antiplatelet agent. Curr Drug Targets 2011, 12:1792-1804.
102. Polena S., Zazzali K.M., Shaikh H.D., et al. Comparison of a point-of-care platelet function testing to light transmission aggregometry in patients undergoing percutaneous coronary intervention pretreated with aspirin and clopidogrel. Point Care 2011, 10:35-39.
103. Hezard N., TessierMarteau A., Macchi L. New insight in antiplatelet therapy monitoring in cardiovascular patients: from aspirin to thienopyridine. Cardiovasc Hematol Disord Drug Targets 2010, 10:224-233.
104. CAPRIE Steering Committee Arandomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996, 348:1329-1339.
105. Mehta S.R., Yusuf S., Peters R.J., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2002, 359:527-533.
106. Steinhubl S.R., Berger P.B., Brennan D.M., CREDO Investigators, et al. Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention. JAm Coll Cardiol 2006, 47:939-943.
107. Sabatine M.S., Cannon C.P., Gibson C.M., et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. NEngl J Med 2005, 352:1179-1189.
108. Chen Z.M., Jiang L.X., Chen Y.P., et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005, 366:1607-1621.
109. Wong Y.W., Prakash R., Chew D.P. Antiplatelet therapy in percutaneous coronary intervention: recent advances in oral antiplatelet agents. Curr Opin Cardiol 2010, 25:305-311.
110. Antman E.M., Wiviott S.D., Murphy S.A., et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. JAm Coll Cardiol 2008, 51:2028-2033.
111. Wallentin L., Becker R.C., Budaj A., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. NEngl J Med 2009, 361:1045-1057.
112. Akers W.S., Oh J.J., Oestreich J.H., et al. Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y12 receptor antagonist. JClin Pharmacol 2010, 50:27-35.
113. Bhatt D.L., Lincoff A.M., Gibson C.M., et al. Intravenous platelet blockade with cangrelor during PCI. NEngl J Med 2009, 361:2330-2341.
114. Harrington R.A., Stone G.W., McNulty S., et al. Platelet inhibition with cangrelor in patients undergoing PCI. NEngl J Med 2009, 361:2318-2329.
115. Linden M.D., Tran H., Woods R., et al. High platelet reactivity and antiplatelet therapy resistance. Semin Thromb Hemost 2012, 38:200-212.
116. Price M.J., Berger P.B., Angiolillo D.J., et al. Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: Design and rationale of the GRAVITAS trial. Am Heart J 2009, 157:818-824.e1.
117. Steinhubl S.R. The illusion of "optimal" platelet inhibition. JACC Cardiovasc Interv 2012, 5:278-280.
118. Dangas G., Colombo A. Platelet glycoprotein IIb/IIIa antagonists in percutaneous coronary revascularization. Am Heart J 1999, 138:S16-S23.
119. Kong D.F., Hasselblad V., Harrington R.A., et al. Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions. Am J Cardiol 2003, 92:651-655.
120. The EPIC Investigators Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. NEngl J Med 1994, 330:956-961.
121. The EPILOG Investigators Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. NEngl J Med 1997, 336:1689-1696.
122. The EPISTENT Investigators Randomised placebo-controlled and balloon-angioplasty-controlled trial toassess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998, 352:87-92.
123. Zimarino M., De Caterina R. Glycoprotein IIb-IIIaantagonists in non-ST elevation acute coronary syndromes and percutaneous interventions: from pharmacology to individual patient's therapy: part1: the evidence of benefit. J Cardiovasc Pharmacol 2004, 43:325-332.
124. Nguyen C.M., Harrington R.A. Glycoprotein IIb/IIIa receptor antagonists: a comparative review of their use in percutaneous coronary intervention. Am J Cardiovasc Drugs 2003, 3:423-436.
125. The ADMIRAL Investigators Three-year duration of benefit from abciximab in patients receiving stents for acute myocardial infarction in the randomized double-blind ADMIRAL study. Eur Heart J 2005, 26:2520-2523.
126. Stone G.W., Grines C.L., Cox D.A., et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. NEngl J Med 2002, 346:957-966.
127. Antoniucci D., Rodriguez A., Hempel A., et al. Arandomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. JAm Coll Cardiol 2003, 42:1879-1885.
128. The GUSTO IV-ACS Investigators Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet 2001, 357:1915-1924.
129. Kastrati A., Mehilli J., Neumann F., et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 Randomized Trial. JAMA 2006, 295:1531-1538.
130. Koutouzis M., Grip L. Glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions. Intervent Cardiol 2010, 2:301-318.
131. The IMPACT-II Investigators Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet 1997, 349:1422-1428.
132. The PURSUIT Trial Investigators Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. NEngl J Med 1998, 339:436-443.
133. The ESPRIT Investigators Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 2000, 356:2037-2044.
134. The RESTORE Investigators Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997, 96:1445-1453.
135. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and SYmptoms (PRISM-PLUS) Study Investigators. Inhibition of the Platelet Glycoprotein IIb/IIIa Receptor with Tirofiban in Unstable Angina and Non-Q-Qave Myocardial Infarction. NEngl J Med 1998, 338:1488-1497.
136. Topol E.J., Moliterno D.J., Herrmann H.C., et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. NEngl J Med 2001, 344:1888-1894.
137. Moliterno D.J., TENACITY Steering Committee and Investigators Arandomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial. Catheter Cardiovasc Interv 2011, 77:1001-1009.
138. Warltier D.C., Kam P.C., Egan M.K. Platelet glycoprotein IIb/IIIa antagonists: pharmacology and clinical developments. Anesthesiology 2002, 96:1237-1249.
139. Coller B.S. Monitoring platelet GP IIb/IIIa antagonist therapy. Circulation 1998, 97:5-9.
140. Wheeler G.L., Braden G.A., Steinhubl S.R., et al. The Ultegra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy. Am Heart J 2002, 143:602-611.
141. Steinhubl S.R., Talley J., David Braden G.A., et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 2001, 103:2572-2578.
142. Tamberella M., Bhatt D., Chew D., et al. Relation of platelet inactivation with intravenous glycoprotein IIb/IIIa antagonists to major bleeding (from the GOLD study). Am J Cardiol 2002, 89:1429-1431.
143. Mascelli M., Lance E., Damaraju L., et al. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation 1998, 97:1680-1688.
144. Tcheng J. Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment. Am Heart J 2000, 139:s38-s45.
145. Schroeder W.S., Gandhi P.J. Emergency management of hemorrhagic complications in the era of glycoprotein IIb/IIIa receptor antagonists, clopidogrel, low molecular weight heparin, and third-generation fibrinolytic agents. Curr Cardiol Rep 2003, 5:310-317.
146. Sperling R.T., Pinto D.S., Ho K.K., et al. Platelet glycoprotein IIb/IIIa inhibition with eptifibatide: prolongation of inhibition of aggregation in acute renal failure and reversal with hemodialysis. Catheter Cardiovasc Interv 2003, 59:459-462.